METHOD FOR PREDICTION OF THE EFFECTIVENESS OF THE AGENT FOR INCREASING THE HIGH-DIFFERENTIATED CELLS IN MAMMARY ADENOCARCINOMA AND THE COMPOSITION FOR ITS IMPLEMENTATION Russian patent published in 2019 - IPC G01N33/53 A61K39/00 A61K39/108 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used to predict the effectiveness of the agent for increasing the relative content of high-differentiated cells in adenocarcinoma of the patient's breast with invasive protocol cancer. Said agent for increasing the high-grade cell content is a composition consisting of phytohemagglutinin P, phytohemagglutinin M, concanavalin A, lipopolysaccharide from Escherichia coli, taken in ratio (pts.wt) 1:1:2:1 respectively (hereinafter – Composition). Concentration of cytokines IL-6, TNF-α and G-CSF in a supernatant of the patient's blood sample incubated with the Composition and without it. Composition effect index is then calculated (CEI_TC) on total production of cytokines IL-6, TNF-α and G-CSF by immunocompetent blood cells by formula: CEI_TC=(A_IL-6+A_TNF-α+A_G-CSF):(B_IL-6+B_TNF-α+B_G-CSF), where A_IL-6, A_TNF-α, A_G-CSF – concentration (pg/ml) of IL-6, TNF-α and G-CSF in the patient's blood sample supernatant incubated with the Composition, and B_IL-6, B_TNF-α, B_G-CSF – concentration of IL-6, TNF-α and G-CSF in a supernatant of a patient's blood sample incubated without Composition. At value of CEI_TC, equal to or greater than 700, an increase in the relative content of high-differentiated cells in the adenocarcinoma of the patient's breast by the Composition is predicted.

EFFECT: use of the given method enables selecting the patients in whom using the Composition it is possible to increase relative content of high-differentiated cells in the tumor and reduce its malignancy; composition has the properties to stimulate differentiation of tumor cells in a number of patients and to stimulate the development of immunocompetent cells of the given group of patients.

1 cl, 3 ex, 2 tbl, 3 dwg